![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Burt Tal Dhillon Savita
Publisher: Future Medicine
ISSN: 1462-2416
Source: Pharmacogenomics, Vol.14, Iss.9, 2013-07, pp. : 1085-1097
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Nateglinide restores early-phase insulin secretion in type 2 diabetes
Inpharma, Vol. 1, Iss. 1272, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Implications of the incidentalome for clinical pharmacogenomics
By Brothers Kyle B Langanke Martin Erdmann Pia
Pharmacogenomics, Vol. 14, Iss. 11, 2013-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmacogenomics and Clinical R&D
By Arnold Hans Peter Hall Susan T
Pharmacogenomics, Vol. 6, Iss. 8, 2005-12 ,pp. :